You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
百誠醫藥(301096.SZ):2024年1-6月公司新增訂單金額7.11億元(含税),同比增長13.38%
格隆匯 08-19 16:30

格隆匯8月19日丨百誠醫藥(301096.SZ)在投資者互動平台表示,截至2024年6月,公司已經立項尚未轉化的自主研發項目近300項,完成小試階段196項,完成中試放大階段40項,在驗證生產階段30項。適應症涵蓋呼吸、消化、感染、腫瘤、精神神經、心血管等多類疾病領域。

公司2024年1-6月公司新增訂單金額71,120.76萬元(含税),同比增長13.38%;公司受託研發服務、研發技術成果轉化及權益分成業務整體實現營業收入51,742.27萬元,相比去年同期增長27.26%。公司將積極響應國家相關政策,密切關注市場動態,加大市場開拓力度,不斷拓展公司業務。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account